Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Updates in the field of bladder cancer from ESMO 2023

Andrea Necchi • 23 Oct 2023
ESMO 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Erdafitinib Pembrolizumab

Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, discusses the novel research and results from recent trials in the field of bladder cancers, touching upon the shift of frontline treatments for metastatic disease, the potential introduction of neoadjuvant combination therapies and targeted agents in early disease settings. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrea Necchi

1:20
Combining ADC’s with other novel agents in the frontline treatment of urothelial carcinoma
Andrea Necchi • 23 Oct 2023
1:26
Screening novel neoadjuvant therapies for urothelial carcinoma
Andrea Necchi • 23 Oct 2023
1:44
Positive biomarkers to select patients for bladder preservation in bladder cancer
Andrea Necchi • 23 Oct 2023
2:00
SunRISe-3: TAR-200 + CET or TAR-200 vs BCG in BCG-naive HR NMIBC
Andrea Necchi • 23 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals